Citadel Advisors
THTX

Citadel Advisors’s Theratechnologies THTX Stock Holding History

Citadel Advisors’s Portfolio THTX Stock Details THTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,000
Closed -$4.92K – 15387
2024
Q3 		$4.92K Buy
+4,000
New +$5.42K ﹤0.01% 13534

Other funds holding THTX

JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CWP
Cyndeo Wealth Partners St. Petersburg, Florida $1.9B AUM 24.89% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GIP
Greatmark Investment Partners Columbus, Georgia $854M AUM 15.72% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM

Citadel Advisors's THTX Position: Q3 2025 in Review

Citadel Advisors sold out of Theratechnologies (THTX) in Q3 2025, closing a stake of 25,250 shares — an estimated $59.6K sold.

Citadel Advisors first reported a position in THTX in Q4 2023 and held it in 5 quarters. The position peaked at $59.6K in Q2 2025. 10 funds tracked by Wall St. Rank hold THTX as of Q3 2025.

  • Citadel Advisors reported no remaining Theratechnologies position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 25,250 Theratechnologies shares in Q3 2025, an estimated $59.6K.
  • Citadel Advisors first reported a position in Theratechnologies in Q4 2023 and held it in 5 quarters.
  • Citadel Advisors's Theratechnologies position peaked at $59.6K in Q2 2025.
  • 10 funds tracked by Wall St. Rank held Theratechnologies as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.